Soluble receptor for advanced glycation end products protects from ischemia- and reperfusion-induced acute kidney injury

Miyagawa, Taro; Iwata, Yasunori; Oda, Megumi; Ogura, Hajime; Sato, Kōichi; Nakagawa, Souichi; Yamamura, Yuta; Kamikawa, Yasutaka; Miyake, Taito; Kitajima, Shinji; Toyama, Tadashi; Hara, Akinori; Sakai, Norihiko; Shimizu, Miho; Furuichi, Kengo; Yamamoto, Yasuhiko; Kaneko, Shuichi; Wada, Takashi

doi:10.1242/bio.058852

Cited by 12 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the study by Helena et al, plasma sRAGE levels were higher in septic patients with AKI than in those without AKI [19]. Recently, Taro et al found that the addition of recombinant sRAGE canceled hypoxia-induced inflammation and promoted cell viability in cultured murine tubular epithelial cells [20]. sRAGE administration might prevent renal tubular damage in ischemia/reperfusion-induced AKI models.…”

Section: Discussionmentioning

confidence: 76%

Decreased Monocyte HLA-DR Expression in Patients with Sepsis and Acute Kidney Injury

Chuang

Liu

et al. 2022

Medicina

View full text Add to dashboard Cite

Background and objectives: Acute kidney injury (AKI) is common in critically ill patients, especially those with sepsis. Persistently low human leukocyte antigen (HLA)-DR expression in monocytes reflects the decreased function of antigen-presenting cells, contributing to poor outcomes in sepsis. This study aimed to establish an association between AKI and HLA-DR expression in monocytes of patients with sepsis. Materials and Methods: We detected HLA-DR expression in monocytes and measured plasma levels of S100A12, high-mobility group box 1 (HMGB1), advanced glycation end products (AGE), and soluble receptor for AGE (sRAGE) from septic patients and healthy controls. Results: HLA-DR expression in monocytes was decreased in patients with AKI than in those without AKI (29.8 ± 5.0% vs. 53.1 ± 5.8%, p = 0.005). Compared with AKI patients, the mean monocyte HLA-DR expression in patients with end-stage renal disease was increased without statistical significance. There were no differences in the AGE/sRAGE ratio and plasma levels of S100A12, HMGB1, AGE, and sRAGE between patients with and without AKI. Conclusions: Compared with septic patients without AKI, patients with AKI had significantly lower HLA-DR expression in monocytes. The role of hemodialysis in monocyte HLA-DR expression needs further studies to explore.

show abstract

Section: Discussionmentioning

confidence: 76%

Decreased Monocyte HLA-DR Expression in Patients with Sepsis and Acute Kidney Injury

Chuang

Liu

et al. 2022

Medicina

View full text Add to dashboard Cite

show abstract

“…One clinical study showed that HMGB1, RAGE and interleukin (IL)-17 expression is increased in the liver tissue of HBV-ACLF patients, and the HMGB1 and RAGE interaction may contribute to inflammation of the liver, enhancing the expression of IL-17 (Jhun et al, 2015). Intriguingly, a recent experimental study showed that compared with wild-type control mice, mice lacking both RAGE and soluble isoforms (sRAGE) had more severe AKI, with enhanced renal tubular damage, macrophage infiltration, and fibrosis (Miyagawa et al, 2022). However, additional mechanisms or pathways are certainly involved, for example, autophagy-mediated HMGB1 release or the novel epigenetic role of HMGB1.…”

Section: Discussionmentioning

confidence: 99%

Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implications

et al. 2023

View full text Add to dashboard Cite

Background: Acute kidney injury (AKI) is a frequent complication in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) and is associated with high rates of mortality. We aimed to estimate serum high mobility group protein 1 (HMGB1) levels in hepatitis B virus-related acute-on-chronic liver failure patients and analyze their clinical value in the development and outcomes of Acute kidney injury.Methods: A total of 251 consecutive patients with hepatitis B virus-related acute-on-chronic liver failure were enrolled in this retrospective study. Using the International Club of Ascites staging criteria of Acute kidney injury, 153 patients developed Acute kidney injury. The clinical data of patients were collected and serum levels of high mobility group protein 1 were measured by ELISA. All patients were followed up until death or for a minimum of 3 months. Early prediction and prognostic implications of high mobility group protein 1 in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Patients with Acute Kidney Injury were investigated in different cohorts, including a propensity score-matched ACLF cohort.Results: Among all individuals with hepatitis B virus-related acute-on-chronic liver failure, the incidence of Acute kidney injury was 61.0% (153/251). The patients who developed stage 2/3 Acute kidney injury showed the highest high mobility group protein 1 levels, followed by those who developed stage 1 Acute kidney injury, and those without Acute kidney injury showed the lowest high mobility group protein 1 levels. Moreover, high mobility group protein 1 levels were significantly higher in non-survivors than in survivors among hepatitis B virus-related acute-on-chronic liver failure patients with Acute kidney injury. Furthermore, analysis of the area under the receiver operating characteristic curve (AUROC) indicated that serum high mobility group protein 1 levels (pre-matching: AUC = 0.740; post-matching: AUC = 0.661) may be a potential predictive factor for Acute kidney injury development and that high mobility group protein 1 (AUC = 0.727) might be a reliable biomarker for prognosis in patients with Acute kidney injury.Conclusion: In patients with hepatitis B virus-related acute-on-chronic liver failure, Acute kidney injury is universal. Acute kidney injury and its stages negatively influence the 90-day transplant-free mortality rate. Serum high mobility group protein 1 levels can serve as a positive predictor of Acute kidney injury development, and high mobility group protein 1 might also be a prognostic biomarker for Acute kidney injury among hepatitis B virus-related acute-on-chronic liver failure patients.

show abstract

“…In contrast, we have recently shown that acute kidney disease in a renal ischemia reperfusion injury model is exacerbated under RAGE-deficient conditions, and hypoxic stress downregulates the expression of both mRAGE and sRAGE/esRAGE in renal tubular cells [47]. Furthermore, recombinant sRAGE administration has been reported to have a renoprotective effect against tubular injury in a renal ischemia reperfusion injury model [47].…”

Section: Rage Isoformsmentioning

confidence: 97%

“…It has been previously reported that RAGE deficiency (i.e., absence of mRAGE and sRAGE) and treatment with purified recombinant sRAGE in mice lead to a protective effect in organs under various pathological conditions, such as acute lung injury, diabetic atherosclerosis, kidney diseases, Alzheimer's disease, and septic shock [2,5,19,55]. In contrast, we have recently shown that acute kidney disease in a renal ischemia reperfusion injury model is exacerbated under RAGE-deficient conditions, and hypoxic stress downregulates the expression of both mRAGE and sRAGE/esRAGE in renal tubular cells [47]. Furthermore, recombinant sRAGE administration has been reported to have a renoprotective effect against tubular injury in a renal ischemia reperfusion injury model [47].…”

Section: Rage Isoformsmentioning

confidence: 97%

“…Nonetheless, exaggerated host immune reactions can cause severe tissue damage and reduce life expectancy; adequate host defense responses would prevent the dissemination of the bacteria and enhance clearance of the bacteria and endotoxin. In terms of physiological function, RAGE was shown to attenuate adaptive inflammation in limb ischemia and kidney ischemia-reperfusion injury using aseptic experimental models [46,47]. In addition, it has been reported that HMGB1-dependent lung epithelial regeneration and repair occur through RAGE [48].…”

Section: Role Of Rage In Physiological and Pathological Processesmentioning

confidence: 99%

See 1 more Smart Citation

Dual Nature of RAGE in Host Reaction and Nurturing the Mother–Infant Bond

Oshima

Harashima

Kimura

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Non-enzymatic glycation is an unavoidable reaction that occurs across biological taxa. The final products of this irreversible reaction are called advanced glycation end-products (AGEs). The endogenously formed AGEs are known to be bioactive and detrimental to human health. Additionally, exogenous food-derived AGEs are debated to contribute to the development of aging and various diseases. Receptor for AGEs (RAGE) is widely known to elicit biological reactions. The binding of RAGE to other ligands (e.g., high mobility group box 1, S100 proteins, lipopolysaccharides, and amyloid-β) can result in pathological processes via the activation of intracellular RAGE signaling pathways, including inflammation, diabetes, aging, cancer growth, and metastasis. RAGE is now recognized as a pattern-recognition receptor. All mammals have RAGE homologs; however, other vertebrates, such as birds, amphibians, fish, and reptiles, do not have RAGE at the genomic level. This evidence from an evolutionary perspective allows us to understand why mammals require RAGE. In this review, we provide an overview of the scientific knowledge about the role of RAGE in physiological and pathological processes. In particular, we focus on (1) RAGE biology, (2) the role of RAGE in physiological and pathophysiological processes, (3) RAGE isoforms, including full-length membrane-bound RAGE (mRAGE), and the soluble forms of RAGE (sRAGE), which comprise endogenous secretory RAGE (esRAGE) and an ectodomain-shed form of RAGE, and (4) oxytocin transporters in the brain and intestine, which are important for maternal bonding and social behaviors.

show abstract

Soluble receptor for advanced glycation end products protects from ischemia- and reperfusion-induced acute kidney injury

Cited by 12 publications

References 38 publications

Decreased Monocyte HLA-DR Expression in Patients with Sepsis and Acute Kidney Injury

Decreased Monocyte HLA-DR Expression in Patients with Sepsis and Acute Kidney Injury

Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implications

Dual Nature of RAGE in Host Reaction and Nurturing the Mother–Infant Bond

Contact Info

Product

Resources

About